ALX Oncology (ALXO) Competitors $1.62 +0.14 (+9.46%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALXO vs. SAGE, JSPR, VALN, FDMT, CCCC, CMPS, IMMP, ACIU, LFCR, and AMLXShould you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Sage Therapeutics (SAGE), Jasper Therapeutics (JSPR), Valneva (VALN), 4D Molecular Therapeutics (FDMT), C4 Therapeutics (CCCC), COMPASS Pathways (CMPS), Immutep (IMMP), AC Immune (ACIU), Lifecore Biomedical (LFCR), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. ALX Oncology vs. Sage Therapeutics Jasper Therapeutics Valneva 4D Molecular Therapeutics C4 Therapeutics COMPASS Pathways Immutep AC Immune Lifecore Biomedical Amylyx Pharmaceuticals Sage Therapeutics (NASDAQ:SAGE) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, community ranking, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment. Is SAGE or ALXO more profitable? ALX Oncology has a net margin of 0.00% compared to Sage Therapeutics' net margin of -317.29%. Sage Therapeutics' return on equity of -50.29% beat ALX Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Sage Therapeutics-317.29% -50.29% -45.48% ALX Oncology N/A -93.02%-70.67% Does the MarketBeat Community believe in SAGE or ALXO? Sage Therapeutics received 582 more outperform votes than ALX Oncology when rated by MarketBeat users. Likewise, 65.39% of users gave Sage Therapeutics an outperform vote while only 62.82% of users gave ALX Oncology an outperform vote. CompanyUnderperformOutperformSage TherapeuticsOutperform Votes63165.39% Underperform Votes33434.61% ALX OncologyOutperform Votes4962.82% Underperform Votes2937.18% Which has better earnings and valuation, SAGE or ALXO? ALX Oncology has lower revenue, but higher earnings than Sage Therapeutics. Sage Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSage Therapeutics$106.40M3.23-$541.49M-$5.58-1.01ALX OncologyN/AN/A-$160.80M-$2.98-0.54 Does the media refer more to SAGE or ALXO? In the previous week, ALX Oncology had 6 more articles in the media than Sage Therapeutics. MarketBeat recorded 12 mentions for ALX Oncology and 6 mentions for Sage Therapeutics. Sage Therapeutics' average media sentiment score of -0.02 beat ALX Oncology's score of -0.17 indicating that Sage Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sage Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral ALX Oncology 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer SAGE or ALXO? Sage Therapeutics presently has a consensus target price of $11.53, suggesting a potential upside of 105.52%. ALX Oncology has a consensus target price of $8.50, suggesting a potential upside of 424.69%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts clearly believe ALX Oncology is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sage Therapeutics 2 Sell rating(s) 16 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00ALX Oncology 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals & insiders hold more shares of SAGE or ALXO? 99.2% of Sage Therapeutics shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 5.5% of Sage Therapeutics shares are owned by insiders. Comparatively, 33.4% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, SAGE or ALXO? Sage Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. SummaryALX Oncology beats Sage Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALXO vs. The Competition Export to ExcelMetricALX OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.44M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-0.5410.5991.3417.19Price / SalesN/A195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book0.435.104.794.78Net Income-$160.80M$151.51M$120.07M$225.60M7 Day Performance11.72%-2.14%-1.90%-1.24%1 Month Performance25.58%-3.13%11.43%3.06%1 Year Performance-87.57%11.51%30.59%16.50% ALX Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALXOALX Oncology3.191 of 5 stars$1.62+9.5%$8.50+424.7%-87.7%$85.44MN/A-0.5440Analyst ForecastNews CoverageGap UpHigh Trading VolumeSAGESage Therapeutics4.1448 of 5 stars$5.22-3.2%$11.53+120.9%-73.1%$319.31M$86.46M-0.97690JSPRJasper Therapeutics2.3333 of 5 stars$21.00+1.9%$73.38+249.4%+290.1%$315.02MN/A-4.3520Positive NewsVALNValneva2.1578 of 5 stars$3.84-2.3%$18.50+381.8%-62.2%$312M$165.52M-30.23700News CoverageHigh Trading VolumeFDMT4D Molecular Therapeutics2.5949 of 5 stars$6.61+1.7%$42.13+537.3%-66.9%$305.57M$17,000.00-2.28201Analyst ForecastCCCCC4 Therapeutics2.0625 of 5 stars$4.32-1.4%$10.00+131.5%-9.2%$304.94M$33.67M-2.58150Analyst UpgradeNews CoveragePositive NewsCMPSCOMPASS Pathways2.8367 of 5 stars$4.36+3.3%$33.60+670.6%-47.3%$298.32MN/A-1.92120Positive NewsIMMPImmutep1.4305 of 5 stars$2.05-6.0%$8.50+314.6%-13.2%$298.19M$5.14M0.002,021ACIUAC Immune2.4761 of 5 stars$2.97+0.7%$12.00+304.0%-33.8%$293.85M$16.48M-6.41140Positive NewsLFCRLifecore Biomedical3.558 of 5 stars$7.75+1.8%$10.00+29.0%+18.7%$285.41M$128.44M97.50690AMLXAmylyx Pharmaceuticals4.2412 of 5 stars$4.16+1.0%$7.33+76.3%-70.7%$285.16M$196.49M-1.08200Short Interest ↓News Coverage Related Companies and Tools Related Companies Sage Therapeutics Competitors Jasper Therapeutics Competitors Valneva Competitors 4D Molecular Therapeutics Competitors C4 Therapeutics Competitors COMPASS Pathways Competitors Immutep Competitors AC Immune Competitors Lifecore Biomedical Competitors Amylyx Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALXO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALXO Stock Alerts